Trial Profile
Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Canagliflozin/teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms CALMER
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
- 09 Apr 2019 Status changed from active, no longer recruiting to completed.